Companies / Allogene Therapeutics, Inc. / Activity
Activity — Allogene Therapeutics, Inc.
28 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Kazam Joshua A Director | Exercise | Common Stock | $0 | +48K +13.60% | 398,463 0.12% of shares | low |
| Feb 2, 2026 | Yoshiyama Annie Executive | Sell | Common Stock | $7.2K | -4K -3.10% | 130,322 0.04% of shares | low |
| Mar 16, 2026 | Beneski Benjamin Machinas Executive | Sell | Common Stock | $11.9K | -5K -2.38% | 198,205 0.06% of shares | low |
| Feb 2, 2026 | Beneski Benjamin Machinas Executive | Sell | Common Stock | $13.1K | -8K -3.47% | 210,172 0.06% of shares | low |
| Mar 2, 2026 | Beneski Benjamin Machinas Executive | Sell | Common Stock | $18.5K | -7K -3.39% | 203,040 0.06% of shares | low |
| Feb 2, 2026 | Douglas Earl Martin Executive | Sell | Common Stock | $40.3K | -23K -3.90% | 564,948 0.16% of shares | low |
| Jan 21, 2026 | Roberts Zachary Executive | Sell | Common Stock | $41.0K | -26K -4.08% | 616,866 0.18% of shares | low |
| Feb 2, 2026 | Parker Geoffrey M. Executive | Sell | Common Stock | $42.2K | -24K -1.88% | 1,252,795 0.36% of shares | low |
| Feb 2, 2026 | Roberts Zachary Executive | Sell | Common Stock | $63.2K | -36K -5.79% | 581,166 0.17% of shares | low |
| Mar 16, 2026 | David D. Chang, M.D., Ph.D. CEO | Sell | Common Stock | $118.0K | -48K -0.92% | 5,150,599 1.49% of shares | medium |
| Feb 2, 2026 | David D. Chang, M.D., Ph.D. CEO | Sell | Common Stock | $171.5K | -95K -1.80% | 5,185,862 1.50% of shares | medium |
| Jun 18, 2026 | Kazam Joshua A Director | Grant | Restricted Stock Unit | — | +95K | 95,400 0.03% of shares | low |
| Jun 18, 2026 | Kazam Joshua A Director | Exercise | Restricted Stock Unit | — | -48K -100.00% | 0 0.00% of shares | low |
| Jun 18, 2026 | Sato Vicki L Director | Grant | Restricted Stock Unit | — | +95K | 95,400 0.03% of shares | low |
| Feb 2, 2026 | Yoshiyama Annie Executive | Grant | Restricted Stock Unit | — | +51K | 50,827 0.01% of shares | low |
| Feb 2, 2026 | Yoshiyama Annie Executive | Grant | Stock Option (Right to buy) | — | +180K | 179,691 0.05% of shares | low |
| Feb 2, 2026 | Beneski Benjamin Machinas Executive | Grant | Restricted Stock Unit | — | +106K | 105,720 0.03% of shares | low |
| Feb 2, 2026 | Beneski Benjamin Machinas Executive | Grant | Stock Option (Right to buy) | — | +374K | 373,757 0.11% of shares | low |
| Feb 2, 2026 | David D. Chang, M.D., Ph.D. CEO | Grant | Restricted Stock Unit | — | +393K | 392,586 0.11% of shares | low |
| Feb 2, 2026 | David D. Chang, M.D., Ph.D. CEO | Grant | Stock Option (Right to buy) | — | +1.4M | 1,387,931 0.40% of shares | low |
| Feb 2, 2026 | Parker Geoffrey M. Executive | Grant | Restricted Stock Unit | — | +152K | 152,480 0.04% of shares | low |
| Feb 2, 2026 | Parker Geoffrey M. Executive | Grant | Stock Option (Right to buy) | — | +539K | 539,072 0.16% of shares | low |
| Feb 2, 2026 | Roberts Zachary Executive | Grant | Restricted Stock Unit | — | +203K | 203,307 0.06% of shares | low |
| Feb 2, 2026 | Roberts Zachary Executive | Grant | Stock Option (Right to buy) | — | +719K | 718,763 0.21% of shares | low |
| Feb 2, 2026 | Douglas Earl Martin Executive | Grant | Restricted Stock Unit | — | +152K | 152,480 0.04% of shares | low |
| Feb 2, 2026 | Douglas Earl Martin Executive | Grant | Stock Option (Right to buy) | — | +539K | 539,072 0.16% of shares | low |
| Feb 2, 2026 | Arie Belldegrun, M.D. Director | Grant | Restricted Stock Unit | — | +263K | 263,033 0.08% of shares | low |
| Feb 2, 2026 | Arie Belldegrun, M.D. Director | Grant | Stock Option (Right to buy) | — | +930K | 929,913 0.27% of shares | low |